Drug Trial Radar · NCT05716087
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
Last checked: Nov 19, 2026Latest source record: Jan 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
62
Planned (sponsor's estimate)
Start
Feb 21, 2023
Primary completion
Dec 5, 2024
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.Industry
- Sponsor type
- Industry
- First posted
- Feb 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
Conditions
- Mantle Cell Lymphoma (MCL)
Interventions
RocbrutinibDrug
Subjects to take Rocbrutinib tablets orally with 240mL water, without food, Once daily.The treatment will continue until progressive disease, unacceptable toxicity, etc.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response RateTime frame: Up to 24 Months
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Affiliated hospital of hebei university
Baoding, China
Beijing Boren Hospital
Beijing, China
Beijing Friendship hospital
Beijing, China
The First Bethune Hospital of Jilin University
Changchun, China
Sichuan Cancer Hospital
Chengdu, China
The First People's Hospital of Foshan
Foshan, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
Sun Yat-sen Memorial Hospital
Guangzhou, China
The First Affiliated Hospital of Soochow University
Suzhou, China
The first affiliated hospital of Wenzhou medical university
Wenzhou, China
Hubei Cancer Hospital
Wuhan, China
Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology
Wuhan, China
Anhui provincial cancer hospital
Hefei, Anhui, China
The first affiliated hospital of Anhui medical university
Hefei, Anhui, China
Peking University Third Hospital
Beijing, Beijing Municipality, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
The first affiliated hospital of Chongqing mediacal university
Chongqing, Chongqing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Fujian Medical university union hospital
Fuzhou, Fujian, China
The first affiliated hospital of Xiamen university
Xiamen, Fujian, China
Gansu provincial cancer hospital
Lanzhou, Gansu, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Meizhou people'shospital
Meizhou, Guangdong, China
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China
The fourth hospital of Hebei medical university
Shijiazhuang, Hebei, China
Harbin First Hospital
Harbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Henan, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Henan provincial people's hospital
Zhengzhou, Henan, China
The first affiliated hospital of Zhengzhou university
Zhengzhou, Henan, China
Hunan cancer hospital
Changsha, Hunan, China
Jiangsu cancer hospital
Nanjing, Jiangsu, China
Jiangsu province hospital
Nanjing, Jiangsu, China
The first affiliated hospital of Nanchang university
Nanchang, Jiangxi, China
The second hospital of dalian medical university
Dalian, Liaoning, China
Shengjing hospital of China medical university
Shenyang, Liaoning, China
The first hospital of China medical university
Shenyang, Liaoning, China
Qilu hospital of Shandong university
Jinan, Shandong, China
Shandong Cancer Hospital
Jinan, Shandong, China
West China School of Medicine
Chengdu, Sichuan, China
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.